KR101359806B1 - Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same - Google Patents
Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same Download PDFInfo
- Publication number
- KR101359806B1 KR101359806B1 KR1020120058747A KR20120058747A KR101359806B1 KR 101359806 B1 KR101359806 B1 KR 101359806B1 KR 1020120058747 A KR1020120058747 A KR 1020120058747A KR 20120058747 A KR20120058747 A KR 20120058747A KR 101359806 B1 KR101359806 B1 KR 101359806B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- potato
- cudrania
- leaf
- complex extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 77
- 239000008280 blood Substances 0.000 title claims abstract description 28
- 210000004369 blood Anatomy 0.000 title claims abstract description 28
- 235000010918 Cudrania tricuspidata Nutrition 0.000 title claims description 4
- 241000208818 Helianthus Species 0.000 title claims description 4
- 241001523380 Maclura tricuspidata Species 0.000 title claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title description 15
- 239000008103 glucose Substances 0.000 title description 14
- 235000013305 food Nutrition 0.000 title description 4
- 230000003247 decreasing effect Effects 0.000 title description 3
- 244000061456 Solanum tuberosum Species 0.000 claims abstract description 54
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract description 54
- 235000015277 pork Nutrition 0.000 claims abstract description 34
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 25
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 8
- 241000218211 Maclura Species 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 235000020510 functional beverage Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- 241000282898 Sus scrofa Species 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000002131 composite material Substances 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 235000012015 potatoes Nutrition 0.000 description 7
- 241000218645 Cedrus Species 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 240000000249 Morus alba Species 0.000 description 5
- 235000008708 Morus alba Nutrition 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000184734 Pyrus japonica Species 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 101000957678 Mus musculus Cytochrome P450 7B1 Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 101000957679 Rattus norvegicus 25-hydroxycholesterol 7-alpha-hydroxylase Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940125716 antipyretic agent Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- -1 sucrose fatty acid ester Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 244000097654 Cudrania tricuspidata Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000016887 Leptospermum scoparium Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 혈당강하에 효능이 있는 돼지감자 및 꾸지뽕잎의 복합추출물에 관한 것으로, 본 발명의 복합추출물은 돼지감자 및 꾸지뽕잎의 함량을 각각의 함량에 비하여 3/10 내지 7/10의 양을 함유하더라도 상승작용에 의해 혈당강하 효과가 매우 뛰어나 당뇨병 치료제로 개발 될 수 있을 뿐만 아니라, 당뇨병 관련 질환의 혈당 개선을 위한 건강기능식품에 이용될 수 있다.The present invention relates to a complex extract of pork potato and courageous leaf extract, which is effective in lowering blood sugar, and the complex extract of the present invention has an amount of 3/10 to 7/10 compared to the respective contents of the pork potato and jacuzzi leaf. Even if it contains, the synergistic effect is excellent in hypoglycemic effect can not only be developed as a diabetes treatment, but also can be used in health functional food for improving blood sugar of diabetes-related diseases.
Description
본 발명은 혈당강하에 효능이 있는 돼지감자(Helianthus tuberous) 및 꾸지뽕잎(Cudrania tricuspidata)의 복합추출물 및 이를 이용한 건강기능식품 조성물에 관한 것이다.
The present invention is a pig potato ( Helianthus) effective in lowering blood sugar tuberous ) and Cudrania leaves tricuspidata ) relates to a complex extract and a dietary supplement composition using the same.
서구화된 식습관과 생활양식의 변화 및 고령화 사회가 도래 하면서 암, 뇌혈관질환, 심장질환 등 각종 성인병이 증가하고 있는 추세이다. 그 중 당뇨병은 유병율이 꾸준히 증가하고 있으며, 급성 및 만성 합병증뿐만 아니라 사망률이 높아 국민건강을 위협하고 있다. 당뇨병은 인슐린의 분비량이 부족하거나 정상적인 기능이 이루어지지 않는 대사질환의 일종으로, 혈중 포도당의 농도가 높아지는 고혈당이 나타나고, 소변으로 포도당을 배출하게 되는 질병으로 크게 췌장 β-세포의 파괴에 의한 인슐린 결핍으로 발생하는 제1형 당뇨병과 인슐린 분비 및 작용의 결함에 의해 발생하는 제2형 당뇨병으로 나눌 수 있다. 이러한 당뇨병에 있어서 췌장 β-세포는 인슐린을 분비하여 혈당을 조절하고, 인슐린 수용체가 존재하여 인슐린 신호전달에 중요한 역할을 담당하고 있으며, 최근 β-세포의 성장과 증식이 당뇨병의 치료와 예방에 영향이 있다는 연구가 보고되고 있다.
With the advent of westernized eating habits, lifestyle changes, and aging societies, various adult diseases such as cancer, cerebrovascular disease, and heart disease are increasing. Among them, the prevalence of diabetes is steadily increasing, and high mortality as well as acute and chronic complications threaten national health. Diabetes is a type of metabolic disease in which insulin secretion is insufficient or does not function normally. Hyperglycemia occurs due to high glucose levels in the blood, and glucose is released into the urine. Insulin deficiency is caused by the destruction of the pancreatic β-cells. It can be divided into type 1 diabetes caused by type 2 diabetes caused by defects in insulin secretion and action. In this diabetes, pancreatic β-cells secrete insulin to regulate blood sugar, insulin receptors are present and play an important role in insulin signaling. Recently, the growth and proliferation of β-cells affect the treatment and prevention of diabetes. Studies have been reported.
우리나라의 경우 인슐린 비의존형의 제2형 당뇨환자가 전체 당뇨환자의 90-95%를 차지하고 있으며 대부분 약물요법으로 혈당을 조절하고 있으나 시간이 경과함에 따라 점점 많은 양의 약물 복용이 요구되므로 부작용이 많기 때문에 이를 예방하기 위해 천연물질로부터 당뇨 개선 기능을 가진 활성 물질의 발굴과 제품 개발의 중요성이 강조되고 있다.
In Korea, insulin-independent type 2 diabetic patients account for 90-95% of all diabetic patients, and most of them control blood sugar by pharmacotherapy, but more and more side effects are required as time passes. Therefore, in order to prevent this, the importance of the discovery of active substances with diabetes improvement function and product development is emphasized.
돼지감자(Helianthus tuberous)는 "뚱단지"라고도 불리는 국화과의 다년생 식물로서 그의 뿌리인 구경을 가리킨 경우도 있다. 원산지는 캐나다 동부 및 미국의 북동부이다. 땅속줄기의 끝이 굵어져서 덩이줄기가 발달한다. 줄기는 곧게 서고 가지가 갈라지며 높이가 1.5∼3m이고 센털이 있다. 잎은 줄기 밑 부분에서는 마주나고 윗부분에서는 어긋나며 긴 타원 모양이고 끝이 뾰족하며 가장자리에 톱니가 있고 밑 부분이 좁아져 잎자루로 흘러 날개가 된다. 덩이줄기는 길쭉한 것에서 울퉁불퉁한 것까지 모양이 매우 다양하고 크기와 무게도 다양하다. 덩이줄기 껍질 색깔도 연한 노란 색·갈색·붉은 색·자주색으로 다양한데, 껍질이 매우 얇아 건조한 공기에 노출하면 금방 주름이 지고 속살이 파삭해진다. 덩이줄기를 식용으로 재배하였으나 지금은 인가 근처에서 야생으로 자라며 일부에서는 가축의 사료로 쓰기 위해 심기도 한다. 한방에서는 뿌리를 국우(菊芋)라는 약재로 쓰는데, 해열 작용이 있고 대량 출혈을 그치게 한다.
Pork Potato ( Helianthus tuberous ) is a perennial plant of the Asteraceae, also called "fatty", sometimes referring to its root, caliber. Country of origin is eastern Canada and northeastern United States. The end of the underground stem is thickened and tubers develop. Stems stand upright, branches are split, height is 1.5 ~ 3m, and there are centriles. The leaves face at the bottom of the stem, are displaced at the top, have a long oval shape, pointed ends, serrated at the edges, and narrow at the bottom to flow into the petioles, becoming wings. Tubers vary in shape from elongated to rugged and vary in size and weight. Tuber shell color also varies from light yellow to brown to red to purple. The skin is so thin that when exposed to dry air, it quickly creases and crusts. Tubers are cultivated for food use, but now they grow wild near permits, and some are planted for livestock feed. In oriental medicine, the root is used as a medicine called gukwoo (菊芋), fever is an action that stops bleeding mass.
또한 최근에 돼지감자의 덩기줄기에 당뇨병 치료 및 합병증 예방에 탁월한 효과가 있어 천연 인슐린이라 불리는 이눌린을 약 15% 이상 함유하고 있는 사실이 나타나면서 다양한 연구가 진행되고 있다. 먼저, 대한민국 공개특허 제2010-33064호에는 돼지감자 추출물을 유효성분으로 포함하는 비만 또는 제2형 당뇨병의 예방 또는 개선용 조성물을 개시하고 있다. 또한 대한민국 공개특허 제2006-41438호, 제2003-26384호 및 제2012-14744호에서는 돼지감자 분말 또는 추출물을 포함하면서 추가적으로 오미자, 대추, 인삼 및 상엽 분말 또는 추출물을 추가하여 당뇨에 효과를 나타냄을 기재하고 있다. 하지만, 이러한 문헌에 나타난 혈당강하 효과는 비교적 탁월한 효과를 나타내고 있지 않다. 따라서 현재에도 돼지감자를 이용한 다양한연구가 진행되고 있다.
In recent years, various studies have been carried out with the fact that the pork stem has an excellent effect on the treatment of diabetes and prevention of complications, containing about 15% or more of inulin called natural insulin. First, Korean Unexamined Patent Publication No. 2010-33064 discloses a composition for preventing or improving obesity or type 2 diabetes, including a pig potato extract as an active ingredient. In addition, Korean Patent Laid-Open Publication Nos. 2006-41438, 2003-26384, and 2012-14744 include the addition of Schisandra potato, jujube, ginseng, and upper leaf powder or extract, showing the effect on diabetes. It is described. However, the hypoglycemic effect shown in these documents does not show a relatively excellent effect. Therefore, a variety of studies are still underway using pig potatoes.
쌍떡잎식물 쐐기풀목 뽕나무과의 낙엽활엽 소교목에 속하는 꾸지뽕(Cudrania tricuspidata)은 굿가시나무라고도 한다. 산기슭의 양지쪽이나 마을 부근에서 자란다. 가지에 가시가 있고, 잎은 3갈래로 갈라진 것과 가장자리가 밋밋하고 달걀 모양인 것이 있다. 3갈래로 갈라지는 잎은 끝이 둔하고 밑이 둥글다. 달걀 모양의 잎은 끝과 밑이 뾰족하고 길이 6∼10cm, 폭 3∼6cm로 표면에 잔털이 있으며 뒷면에는 융모(絨毛:길이가 일정하지 않은 털이 서로 엉킨 것)가 있다. 잎자루의 길이는 15∼25mm로 털이 있다. 잎은 뽕잎 대용으로 쓰고, 열매는 먹을 수 있으며 잼을 만들거나 술을 담그고, 나무껍질과 뿌리는 약용이나 종이 원료로 쓴다.
Cudrania tricuspidata belonging to the deciduous broad-leaved subfamily of Dicotyledonous nettle, Mulberry family, is also known as Goodthorn Tree. It grows in the foothills and near the village. The branches have thorns, and the leaves are divided into three branches, and the edges are flat and egg-shaped. The three-branched leaf is dull at the end and rounded at the bottom. The egg-shaped leaves are sharp at the ends and bottom, 6-10cm long, 3-6cm wide, with fine hairs on the surface, and villi on the back are entangled with each other. Petioles are 15-25mm long, with hairs. The leaves are used as a mulberry leaf substitute, the fruit can be eaten, jam or soaked, and the bark and roots are used as medicinal or paper ingredients.
꾸지뽕나무의 뿌리껍질, 나무질부, 나무껍질 및 잎에는 인체에 유효한 다양한 성분이 포함되어 있어서, 전래로부터 꾸지뽕나무는 그 뿌리, 껍질, 줄기, 잎, 나무껍질, 열매 등 부위에 따라 혈압강하제, 결핵치료제, 해열제, 건해제, 거담제, 이뇨제, 지혈제, 거풍제 등의 약재로 이용 되었으며, 항진균제로서 무좀에 사용하고 소화기관의 허약에 의한 만성소화불량에 이용되고 있다. 또한 줄기 껍질에는 폐암, 대장암, 피부암, 자궁암 등에 효과가 좋은 성분이 다량 함유되어 있다고 보고되고 있다. 꾸지뽕나무는 항암효과가 있는 것으로 알려진 플라노보이드를 함유하고 있어서 약재로 동의보감, 약성감, 본초강목 등에서 고대로부터 널리 알려져 있다.
Root bark, tree bark, bark and leaves of Cudrania japonica contain various ingredients effective for the human body. From now on, Cudrania japonica is a blood pressure lowering agent, tuberculosis depending on the root, bark, stem, leaf, bark, fruit, etc. It has been used as a medicine for antipyretics, antipyretics, expectorants, diuretics, hemostatics, and antiperspirants. It is used for athlete's foot as an antifungal agent and for chronic dyspepsia due to weakness of digestive organs. In addition, stem bark has been reported to contain a large amount of ingredients effective in lung cancer, colon cancer, skin cancer, uterine cancer. Cudrania japonica is known as anti-cancer effect, because it contains a flanovoid known as an anticancer effect, synonymous bogam, weakness, herbal wood, etc. from ancient times.
최근 지속적으로 꾸지뽕나무로부터의 추출물을 이용한 다양한 연구가 지속되고 있으며, 논문 J East Asian Soc Dietary Life, 18(4): 516~523 (2008)에서는 꾸지뽕잎으로 제조한 덖음차와 발효차의 항당뇨 효과를 기재하고 있고 대한민국 공개특허 제2012-26992호에는 꾸지뽕 추출물 및 의이인 추출물을 포함하는 비만과 당뇨 억제 효과를 개시하고 있다. 또한, 대한민국 등록특허 제10-815212호에서는 혈당 및 체중을 조절할 수 있는 꾸지뽕잎 추출물과 난소화성 말토덱스트린의 배합물이 제공되고 있다. 하지만, 이러한 문헌에 나타난 혈당강하 효과는 비교적 미비한 효과를 나타내고 있다. 따라서 현재에도 꾸지뽕을 이용한 다양한 연구가 진행되고 있다.
Recently, various studies using extracts from courageous tree have been continuously conducted, and in the paper J East Asian Soc Dietary Life, 18 (4): 516 ~ 523 (2008), the anti-diabetic effect of tea and fermented tea made from coupe leaf Korean Patent Laid-Open Publication No. 2012-26992 discloses an effect of inhibiting obesity and diabetes, including kkujippong extract and Euiyiin extract. In addition, the Republic of Korea Patent No. 10-815212 is provided with a combination of kkujippong leaf extract and indigestible maltodextrin that can control blood sugar and weight. However, the hypoglycemic effect shown in these documents shows a relatively insignificant effect. Therefore, a variety of researches are still underway using coujippong.
본 발명자들은 당뇨병 환자의 혈당을 개선할 수 있는 건강기능식품 조성물을 연구하던 중에 돼지감자 및 꾸지뽕을 혼합한 추출물은 함량을 각각의 반량 정도 함유하더라도 상승 작용에 의해 혈당강하에 현저히 탁월한 효과를 나타냄을 확인하고 본 발명을 완성하게 되었다.
The inventors of the present invention while studying a health functional food composition that can improve the blood sugar of diabetics, even if the extract of pig potato and kkujippong contains about half each of the content shows a significant effect on the blood sugar drop by synergism It confirmed and completed this invention.
본 발명은 혈당강하에 효능이 있는 돼지감자 및 꾸지뽕잎의 복합추출물 및 이를 이용한 건강기능식품 조성물을 제공하는 것이다.
The present invention is to provide a composite extract of swine potato and cooji mulberry leaves effective in lowering blood sugar and health functional food composition using the same.
상기와 같은 목적을 달성하기 위하여, 본 발명은 건조된 돼지감자 및 꾸지뽕잎의 복합추출물을 제공한다.
In order to achieve the above object, the present invention provides a composite extract of dried pork potato and kkujippong leaves.
또한, 본 발명에 따른 복합추출물을 함유하는 건강기능식품 조성물을 제공한다.
In addition, it provides a health functional food composition containing a complex extract according to the present invention.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 건조된 돼지감자 및 꾸지뽕잎을 혼합하고 추출하여 복합추출물을 제조한다. 본 발명에서 복합추출물을 제조하기 위해 사용한 건조된 돼지감자 및 꾸지뽕잎의 함량은 각각 의 함량에 비하여 3/10 내지 7/10의 양을 함유하며, 그 함량비는 3:7 내지 7:3 중량%이고, 가장 바람직한 복합추출물의 함량은 돼지감자 및 꾸지뽕잎이 4:6 내지 6:4 중량%을 함유하여 제조하는 것이다.
The present invention is to prepare a composite extract by mixing and extracting dried pork potato and kkujippong leaves. In the present invention, the contents of the dried pork potato and Cudrania leaf used to prepare the complex extract contain an amount of 3/10 to 7/10 relative to the respective content, and the content ratio is 3: 7 to 7: 3 weight %, The most preferred content of the composite extract is to prepare the pork potato and kkujippong leaves containing 4: 6 to 6: 4% by weight.
본 발명에 따른 추출방법은 한약제제 및 천연물 사용시 제조하는 통상적인 추출방법을 사용하여 제조 할 수 있다. 추출 방법으로는 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출 및 증기 추출로 이루어진 군으로부터 선택된 어느 하나인 것이 바람직하나 이에 한정되지 않는다. 바람직한 추출방법은 열수 추출방법이다.
Extraction method according to the invention can be prepared using conventional extraction methods prepared when using herbal medicines and natural products. The extraction method is preferably any one selected from the group consisting of hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction and steam extraction, but is not limited thereto. Preferred extraction method is hot water extraction method.
본 발명은 돼지감자 및 꾸지뽕잎을 3:7 내지 7:3 중량%, 바람직하게는 복합추출물의 함량은 돼지감자 및 꾸지뽕잎이 4:6 내지 6:4 중량%을 함유하며, 약학적으로 허용 가능한 담체, 희석제 또는 부형제를 포함하여 당뇨병의 예방 및 치료용 제제로 제제화 할 수 있다.
The present invention is 3: 7 to 7: 3% by weight of pig potatoes and Cudrania leaves, preferably the content of the composite extract contains 4: 6 to 6: 4% by weight of pig potatoes and Cudrania leaves, pharmaceutically acceptable Possible carriers, diluents or excipients may be formulated into preparations for the prevention and treatment of diabetes.
본 발명에 따른 제제화에 필요한 생약 추출물은 조성물 총 중량에 대하여 상기 추출물을 0.01 내지 80%, 바람직하게는 1 내지 50% 중량으로 포함한다.
The herbal extract required for formulation according to the present invention comprises 0.01 to 80%, preferably 1 to 50% by weight of the extract relative to the total weight of the composition.
본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아고무, 알지네이트, 젤라틴, 칼슘포스페이트, 칼슘실리케이트, 셀룰로즈, 메틸셀룰로즈, 미정질셀룰로스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘스테아레이트 및 광물유를 들 수 있다.
Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
또한, 본 발명의 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.
In addition, the compositions of the present invention may be used in the form of oral dosage forms, external preparations, suppositories, or sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods. Can be.
상세하게는, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 생약 복합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.
More specifically, when formulating the composition, it can be prepared using a diluent or an excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. Can be prepared by mixing. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, syrups and the like, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used diluents such as water and liquid paraffin . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
본 발명의 복합추출물은 환자의 나이, 성별, 체중에 따라 달라질 수 있으나, 일반적으로 0.01 내지 10g/㎏의 양, 바람직하게는 1 내지 5g/㎏의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 또한 그 투여량은 투여경로, 질병의 정도, 성별, 체중, 나이, 건강상태, 식이, 투여시간, 투여방법, 배설율 등에 따라서 증감될 수 있다. 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.
The complex extract of the present invention may vary depending on the age, sex, and weight of the patient, but in general, an amount of 0.01 to 10 g / kg, preferably 1 to 5 g / kg, may be administered once or several times a day. have. In addition, the dosage may be increased or decreased depending on the route of administration, degree of disease, sex, weight, age, health condition, diet, administration time, administration method, excretion rate, and the like. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.
또한, 본 발명에 따른 복합추출물을 함유하는 당뇨환자를 위한 건강기능식품은 상기 제조한 복합추출물을 주성분으로 함유하고, 상기한 성분 외에 식품학적으로 허용되는 첨가물이나 부형제를 포함할 수 있다. 이 때 식품학적으로 허용되는 첨가물과 부형제로는 비타민 B1, 비타민 B2, 비타민 C, 비타민 B6, 니코틴산아미드, 구연산, 액상과당, 스테비오사이드, 말토덱스트린, 마뉴카벌꿀, 사과농축액, 락추로오스 분말, 실리코알루민산나트륨, 자당지방산에스테르, 히드록시프로필메칠셀룰로오스, 글리세린지방산에스테르, 산화아연, 베타-시클로덱스트린 등이 있다.
In addition, the health functional food for diabetic patients containing the complex extract according to the present invention contains the prepared complex extract as a main ingredient, and may include food additives or excipients that are acceptable in addition to the above components. At this time, food additives and excipients which are acceptable in the food industry include vitamin B1, vitamin B2, vitamin C, vitamin B6, nicotinamide, citric acid, liquid fructose, stevioside, maltodextrin, manuka honey, apple concentrate, lacchurose powder, Sodium silicate, sucrose fatty acid ester, hydroxypropyl methyl cellulose, glycerin fatty acid ester, zinc oxide, beta-cyclodextrin and the like.
본 발명의 복합추출물은 통상적으로 알려진 방법에 의하여 다양한 형태의 건강기능식품으로 제조될 수 있고, 예를 들면 액제(음료, 파우치), 정제, 환제, 경질캡슐제, 연질캡슐제, 과립제 등으로 제조될 수 있다.
The complex extract of the present invention can be prepared in various forms of health functional food by a commonly known method, for example, liquid (beverage, pouch), tablets, pills, hard capsules, soft capsules, granules, etc. Can be.
본 발명에 따른 돼지감자 및 꾸지뽕잎의 복합추출물은 혈당강하에 탁월한 효능이 있어, 당뇨병 치료제로 개발 될 수 있을 뿐만 아니라, 당뇨 환자의 혈당을 개선하기 위한 건강기능식품 조성물로 유용하게 사용할 수 있다.
The complex extract of pork potato and jjippong leaf according to the present invention has excellent efficacy in lowering blood sugar, and can be used as a health functional food composition for improving blood sugar of diabetics as well as being developed as a diabetes treatment.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.
However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the present invention is not limited to the following Examples and Experimental Examples.
<< 실시예Example 1> 1> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(5:5 중량%)의 제조 Preparation of Complex Extract (5: 5 wt%)
돼지감자 2kg을 정제수로 세척한 후, 세절기를 이용하여 10~15mm로 얇게 세절하고 60℃에서 약 1시간 건조 시켰다. 별로도 꾸지뽕잎 2kg을 정제수로 세척한 후 60℃에서 약 1시간 건조 시켰다. 건조된 돼지감자 500g 및 꾸지뽕잎 500g(주성분 중량 대비=5:5 중량 %)에 중량 대비 8배량의 정제수를 첨가하고, 95℃에서 5시간 동안 2회 추출을 실시한 후 여과하여 40 Brix 로 감암 농축하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.
After washing 2kg of pork potatoes with purified water, thinly sliced into 10 ~ 15mm using a washing machine and dried at 60 ℃ for about 1 hour. Separately kkujippong 2kg was washed with purified water and dried at 60 ℃ for about 1 hour. 500g of dried pork potato and 500g of Cudrania leaves (5: 5% by weight of main ingredient) were added with 8 times the amount of purified water, extracted twice at 95 ° C for 5 hours, filtered and concentrated to 40 Brix. To prepare a pig and potato kkujippong complex extract.
<< 실시예Example 2> 2> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(3:7 중량%)의 제조 Preparation of Complex Extract (3: 7 wt%)
실시예 1과 동일한 방법으로 건조시킨 돼지감자 300g 및 꾸지뽕잎 700g(주성분 중량 대비=3:7)을 배합하여 실시예 1의 방법과 동일하게 제조하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.The same method as in Example 1 was prepared by combining 300 g of dried pork potatoes and 700 g of Cudrania leaf (compare the main component weight = 3: 7) in the same manner as in Example 1, thereby preparing a complex extract of Porcine Potato and Cudrania leaf.
<< 실시예Example 3> 3> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(4:6 중량%)의 제조 Preparation of Complex Extract (4: 6 wt%)
실시예 1과 동일한 방법으로 건조시킨 돼지감자 400g 및 꾸지뽕잎 600g(주성분 중량 대비=4:6)을 배합하여 실시예 1의 방법과 동일하게 제조하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.In the same manner as in Example 1, 400 g of dried pork potato and 600 g of Cudrania leaf (compared to the main component weight = 4: 6) were prepared in the same manner as in Example 1, thereby preparing a composite extract of Porcine Potato and Cudrania leaf.
<< 실시예Example 4> 4> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(6:4 중량%)의 제조 Preparation of Complex Extract (6: 4 wt%)
실시예 1과 동일한 방법으로 건조시킨 돼지감자 600g 및 꾸지뽕잎 400g(주성분 중량 대비=6:4)을 배합하여 실시예 1의 방법과 동일하게 제조하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.In the same manner as in Example 1, the dried pork potato 600g and 400g Cudrania leaf 400g (compared to the main component weight = 6: 4) was prepared in the same manner as in Example 1 to prepare a pig and Cudrania leaf composite extract.
<< 실시예Example 5> 5> 돼지감자와 Pork Potato and 꾸지뽕잎Cedar leaf 복합추출물(7:3 중량%)의 제조 Preparation of Complex Extract (7: 3 wt%)
실시예 1과 동일한 방법으로 건조시킨 돼지감자 700g 및 꾸지뽕잎 300g(주성분 중량 대비=7:3)을 배합하여 실시예 1의 방법과 동일하게 제조하여 돼지감자와 꾸지뽕잎 복합추출물을 제조하였다.
In the same manner as in Example 1 700g dried pork potato and 300g kkujippong leaf 300g (compared to the main component weight = 7: 3) was prepared in the same manner as in Example 1 to prepare a pig extract and kkujippong leaves complex extract.
<< 비교예Comparative Example 1> 돼지감자 추출물의 제조 1> Preparation of Pork Potato Extract
돼지감자 2kg을 정제수로 세척한 후, 세절기를 이용하여 10 ~ 15mm로 얇게 세절하고 50 ~ 60℃의 온도를 갖는 건조기에서 약 1시간 건조 시켰다. 건조된 돼지감자 1kg에 중량 대비 5배량의 정제수를 첨가하고, 95℃에서 4 ~ 5시간 동안 2회 추출을 실시한 후 여과하여 40 Brix 로 감암 농축하여 돼지감자 추출물을 제조하였다.
After washing 2kg of pork potatoes with purified water, thinly sliced into 10 ~ 15mm using a washing machine and dried for about 1 hour in a dryer having a temperature of 50 ~ 60 ℃. 5 kg purified water was added to 1 kg of dried pork potatoes, extracted twice at 95 ° C. for 4 to 5 hours, filtered and concentrated to 40 Brix to prepare pork extract.
<< 비교예Comparative Example 2> 2> 꾸지뽕잎Cedar leaf 추출물의 제조 Preparation of extract
꾸지뽕잎 2kg을 정제수로 세척한 후 50 ~ 60℃의 온도를 갖는 건조기에서 약 1시간 건조 시켰다. 건조된 꾸지뽕잎 1kg에 중량 대비 5배량의 정제수를 첨가하고 95℃에서 3 ~ 4시간 동안 2회 추출을 실시한 후 여과하여 40 Brix 로 감암 농축하여 꾸지뽕잎 추출물을 제조하였다.
After washing with 2kg of kkujippong leaves with purified water it was dried for about 1 hour in a dryer having a temperature of 50 ~ 60 ℃. 5 kg of purified water was added to 1 kg of dried Cudrania leaf, and extracted twice at 3 ° C. for 3-4 hours at 95 ° C., followed by filtration and concentrated to 40 Brix to prepare Cudrania leaf extract.
본 발명에 의해 제조된 돼지감자와 꾸지뽕잎 복합추출물의 실시예 1 내지 5 및 비교예 1 및 2를 통해 제조된 돼지감자 추출물 및 꾸지뽕잎 추출물의 주성분 함량비를 하기 표 1에 나타내었다.
Table 1 shows the main component content ratios of the pork potato extract and Cudrania leaf extract prepared by Examples 1 to 5 and Comparative Examples 1 and 2 of the pork potato and Cudrania leaf composite extract prepared by the present invention.
본 발명을 통해 제조된 돼지감자와 꾸지뽕잎 복합추출물인 각각의 실시예 1 내지 5 및 돼지감자 추출액의 비교예 1과 꾸지뽕잎 추출물인 비교예 2를 하기의 실험예를 통해 혈당강하 효과를 확인하였다.
The blood glucose lowering effect was confirmed through the following experimental examples of Comparative Examples 1 and Comparative Example 2 of the Pork Potato and Cudrania leaf complex extract prepared according to the present invention, Examples 1 to 5 and the Porcine Potato Extract extract. .
<< 실험예Experimental Example 1> 1> 혈당 강하 효과 시험Hypoglycemic effect test
1. 실험동물1. Experimental animals
실험동물은 약 4주령이 된 Sparague-Dawley 종 흰쥐 수컷을 7일간 고형사료(pellet)로 사육하면서 환경에 적응시켰다. 1주일간 안정시킨 후 6주령(체중:150~170g)이 되었을 때 실험동물을 난괴법(randomized complete block design)에 의하여 7마리를 1개군으로 하여 9개군으로 나누고 1군의 정상군과 8군의 당뇨유발군으로 분리하였다. 즉, 당뇨를 유발하지 않고 증류수를 자유 음수시킨 normal군, STZ로 당뇨를 유발한 후 증류수를 자유 음수시킨 STZ-control군, 당뇨유발 흰쥐에 돼지감자 추출물을 투여한 군(HT군, 비교예 1), 당뇨유발 흰쥐에 꾸지뽕잎 추출물(CT군, 비교예 2)을 투여한 군, 당뇨유발 흰쥐에 주성분 배합 비율별로 혼합한 돼지감자와 꾸지뽕잎 복합추출물을 자유 음수시킨 HCT-1군(3:7, 실시예 2), HCT-2군(4:6, 실시예 3), HCT-3군(5:5, 실시예 1), HCT-4군(6:4, 실시예 4), HCT-5군(7:3, 실시예 5)으로 구분하여 사육하였다.
The experimental animals were adapted to the environment by breeding male Sparague-Dawley rats, about 4 weeks old, as pellets for 7 days. After 6 weeks of stabilization for 1 week (weight: 150-170g), the experimental animals were divided into 9 groups with 1 group by the randomized complete block design. Diabetic isolates. That is, the normal group free of distilled water without causing diabetes, the STZ-control group free of negative distilled water after inducing diabetes with STZ, the group of pig potato extracts administered to diabetic rats (HT group, Comparative Example 1 ), HCT-1 group free of negatively mixed pig potato and Cudrania leaf complex extracts mixed with the main components in the diabetic rats (C group, Comparative Example 2) administration group, diabetic rats. 7, Example 2), HCT-2 group (4: 6, Example 3), HCT-3 group (5: 5, Example 1), HCT-4 group (6: 4, Example 4), HCT -5 groups (7: 3, Example 5) were divided and bred.
2. 스트렙토조토신(STZ)에 의한 당뇨유발2. Diabetes Induction by Streptozotocin (STZ)
당뇨를 유발시키기 위하여 16시간 실험동물을 절식시킨 후, 췌장의 β-세포만을 특이적으로 작용하여 다른 기관에 영향을 미치지 않는다고 알려진 STZ(Sigma Chemical Co.)(Wright&Lacy 1988)을 pH4.5의 0.01M citrate buffer에 45mg/kg B.W.농도로 녹여 꼬리 정맥에 주사하였다. 정상군은 동량의 0.01M citrate buffer 용액을 주사하였다. STZ 을 주사한 후 약 7시간이 지나면 혈당량이 급격히 감소하고 인슐린 농도가 상승하다가 서서히 혈당이 상승되고 β-세포의 파괴로 인하여 인슐린 농도가 감소되며 48시간이 경과된 후에는 고혈당 상태가 지속되므로, 주사 후 48시간 후에 꼬리 정맥에서 혈액을 채취하여 혈당 측정기로 혈당 농도를 측정하여 혈당 농도가 300mg/㎗이상인 것을 당뇨가 유발된 것으로 확인하여 실험에 사용하였다.
After fasting the experimental animals for 16 hours to induce diabetes, STZ (Sigma Chemical Co.) (Wright & Lacy 1988), which is known to specifically act on only the β-cells of the pancreas and does not affect other organs, has a pH of 0.01. It was dissolved in 45 mg / kg BW concentration in citrate buffer and injected into the tail vein. Normal group was injected with the same amount of 0.01M citrate buffer solution. About 7 hours after the injection of STZ, blood glucose level rapidly decreases, insulin concentration rises, then blood glucose level rises, insulin concentration decreases due to the destruction of β-cells, and hyperglycemic state persists after 48 hours. After 48 hours after injection, blood was collected from the tail vein and the blood glucose level was measured using a blood glucose meter to determine that the blood glucose concentration was 300 mg / ㎗ or more, and it was used in the experiment.
3. 실험식이3. Experimental diet
식이 섭취량은 매일 일정한 시간에 칭량하여 1일 섭취한 식이의 양을 측정하고 1주일 단위로 주당 1일 평균 식이 섭취량을 구하였으며, 체중은 1주일에 한번씩 일정한 시간에 동물용 체중계로 측정하였으며, 식이효율(feed efficiency ratio:FER)은 체중 증가량을 식이섭취량으로 나누어서 구하였다.
The dietary intake was measured at a certain time every day to measure the amount of diet consumed per day, and the average daily intake per week was obtained on a weekly basis, and the weight was measured on an animal scale at a regular time once a week. The feed efficiency ratio (FER) was obtained by dividing weight gain by dietary intake.
4. 혈중 포도당 측정4. Blood glucose measurement
혈중 포도당 농도는 미정맥으로부터 체혈한 핼액을 Pre-cision Q·I·D ®Blood Glucose Monitoring System (Medisense Inc. USA)으로 직접 측정하여 각각의 실시예 1 내지 5 및 비교예 1 내지 2에 대한 혈당강하 효과를 하기 표 2에 나타내었다.
Blood glucose concentrations of the glucose haelaek chehyeol from a vein in US Pre-cision Q · I · D ® Blood Glucose Monitoring System embodiment (Medisense Inc. USA) by direct measurement of each of Examples 1 to 5 and Comparative Examples 1 to 2 The dropping effect is shown in Table 2 below.
상기 표 2에서 알 수 있는 바와 같이, 돼지감자 및/또는 꾸지뽕잎 추출물을 함유하는 모든 실험군은 정상군에 비하여 높은 혈당 수준을 나타내었다. 실험 3주까지는 STZ-control군과 실험식이(추출물)를 투여한 실험군 사이에 유의적인 차이는 나타나지 않았으나, 실험 4주 후부터 시작하여 STZ-control군과 비교하여 STZ-contro+HT군, STZ-control+CT군, HCT-1 내지 5군 모두 혈당치가 감소됨을 확인할 수 있었다.
As can be seen in Table 2, all experimental groups containing pig potato and / or kkujippong leaf extract showed a higher blood sugar level than the normal group. There was no significant difference between the STZ-control group and the experimental group (extract) administered up to 3 weeks, but after 4 weeks, the STZ-contro + HT and STZ-control groups were compared with the STZ-control group. In the + CT group, HCT-1 to 5 groups, it was confirmed that the blood glucose level was reduced.
하지만, 돼지감자 또는 꾸지뽕잎 추출물을 단독으로 함유하는 비교예 1 및 비교예 2에서 제조된 단일추출물 투여군(STZ-contro+HT군, STZ-control+CT군)에서는 혈당치가 감소하는 것은 확인 되었지만 STZ-control군과 비교하여 현저하게 감소하는 효과는 아닌 것을 알 수 있다.
However, in the single extract administration group (STZ-contro + HT group, STZ-control + CT group) prepared in Comparative Example 1 and Comparative Example 2 containing porcine potato or Cudrania leaf extract alone, it was confirmed that the blood glucose level was decreased. It can be seen that the effect is not significantly reduced compared to the -control group.
반면에, 본 발명의 실시예 1 내지 5를 통해 제조된 돼지감자 및 꾸지뽕잎 복합 추출물의 경우에는 돼지감자 또는 꾸지뽕잎 단독 추출물 보다 각각 3/10 내지 7/10 중량부 감소된 양을 혼합하여 돼지감자 또는 꾸지뽕잎 추출물의 양과 동일하게 혼합하여 투여한 것임에도 불구하고 STZ-control군 및 비교예 1 및 비교예 2에서 제조된 단일추출물 투여군(STZ-contro+HT군, STZ-control+CT군)과 비교하여 현저하게 감소되는 것을 확인 할 수 있다. 특히 본 발명의 실시예 1 및 실시예 3 내지 4에서 제조한 돼지감자 및 꾸지뽕잎의 주성분 함량이 돼지감자 또는 꾸지뽕잎 단독 추출물 보다 각각 2/50 내지 3/5 중량부 감소된 양을 혼합하여 4:6 내지 6:4에 해당하는 복합추출물을 투여한 HCT-2 내지 4군에서는 현저한 혈당 강하 효과를 나타내었다.
On the other hand, in the case of the porcine potato and kkujippong leaf complex extract prepared in Examples 1 to 5 of the present invention, the mixture by reducing the amount of 3/10 to 7/10 parts by weight than the pig potato or kkujippong leaf alone extract, respectively Despite being administered in the same amount as the amount of potato or Cudrania leaf extract, the STZ-control group and the single extract administration group prepared in Comparative Examples 1 and 2 (STZ-contro + HT group, STZ-control + CT group) It can be seen that it is significantly reduced in comparison with. In particular, the main components of the pork potato and kkujippong leaves prepared in Examples 1 and 3 to 4 of the present invention by mixing 2/50 to 3/5 parts by weight of the reduced amount of each compared to the pig potato or kkujippong leaves alone extract 4 In the HCT-2 to 4 groups administered the complex extract corresponding to: 6 to 6: 4, there was a significant hypoglycemic effect.
따라서 본 발명은 돼지감자 및 꾸지뽕잎의 중량 기준(%)으로 4 : 6 내지 6 : 4의 복합비율을 가지는 복합 추출물이 돼지감자 또는 꾸지뽕잎 각각의 추출물에 비하여 혈당강하에 탁월한 효과가 나타내어 당뇨병 치료제로 개발 될 수 있을 뿐만 아니라, 당뇨병 관련 질환의 건강기능식품 조성물로 유용하게 사용할 수 있다.
Therefore, the present invention exhibits an excellent effect on the hypoglycemic effect of the complex extract having a complex ratio of 4: 6 to 6: 4 on the basis of the weight (%) of the pork potato and cooji mulberry leaves compared to the respective extracts of pig potato or coo zippong leaves Not only can be developed, it can be usefully used as a dietary supplement composition of diabetes-related diseases.
하기 제조예는 본 발명의 돼지감자 및 꾸지뽕잎의 복합추출물을 함유하는 여러 제형의 예를 나타낸 것이며, 아래의 제제예는 본 발명을 예시하는 것일 뿐, 이에 의해 본 발명의 내용이 제한되는 것은 아니다.
The following preparation examples show examples of various formulations containing the complex extract of pork potato and cooji mulberry leaves of the present invention, the following preparation examples are merely to illustrate the present invention, thereby not limiting the contents of the present invention .
<제제예 1> 산제의 제조Preparation Example 1 Preparation of Powder
실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1
옥수수전분 100mgCorn Starch 100mg
유 당 100mgLactose 100mg
탈 크 10mgTalc 10mg
상기의 성분들을 혼합하고 기밀 포에 충진 하여 산제를 제조한다.
The above ingredients are mixed and filled in airtight cloth to prepare a powder.
<제제예 2> 정제의 제조≪ Formulation Example 2 > Preparation of tablet
실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1
옥수수전분 100mgCorn Starch 100mg
유 당 100mgLactose 100mg
스테아린산 마그네슘 2mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
<제제예 3> 캡슐제의 제조≪ Formulation Example 3 > Preparation of capsules
실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1
유 당 50mgLactose 50mg
스테아린산 마그네슘 1mg1 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 캡슐제의 제조방법에 따라서 타정하여 젤라틴 캡슐제에 충진 하여 제조한다.
After mixing the above components is compressed into a gelatin capsule prepared by the compression method according to the conventional manufacturing method of the capsule.
<제제예 4> 액제의 제조Preparation Example 4 Preparation of Liquid
실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1
이성화당 10g10g per isomerization
서 당 10g10g per book
레몬향 적량Lemon incense quantity
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라서 정제수에 각각의 성분을 가하고 용해시키고 레몬향을 적량 가한 다음 정제수를 가하여 전체를 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜서 액제를 제조한다.
According to the conventional method for preparing a liquid solution, each component is added to the purified water, dissolved, and lemon flavor is added, and then purified water is added to adjust the total amount to 100 ml, and then filled into a brown bottle to prepare a liquid solution.
<제제예 5> 건강 식품의 제조Preparation Example 5 Preparation of Health Food
실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 ㎍70 [mu] g of vitamin A acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎0.13 mg vitamin B1
비타민 B2 0.15 ㎎0.15 mg of vitamin B2
비타민 B6 0.5 ㎎0.5 mg vitamin B6
비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12
비타민 C 10 ㎎10 mg vitamin C
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 50 ㎍50 ㎍ of folic acid
판토텐산 칼슘 0.5 ㎎Calcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 ㎎1.75 mg of ferrous sulfate
산화아연 0.82 ㎎0.82 mg of zinc oxide
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎15 mg of potassium phosphate monobasic
제2인산칼슘 55 ㎎Secondary calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium citrate 90 mg
탄산칼슘 100 ㎎100 mg of calcium carbonate
염화마그네슘 24.8 ㎎24.8 mg of magnesium chloride
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.
The composition ratio of the above-mentioned vitamin and mineral mixture is composed of a relatively suitable ingredient suitable for health food as a preferred example, but the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method, and then granulated. It can be prepared and used in the manufacture of health food compositions according to conventional methods.
<제제예 6> 건강 음료의 제조Preparation Example 6 Preparation of Healthy Drinks
실시예 1의 복합추출물 100mg100 mg of the composite extract of Example 1
강활 추출물 1000 ㎎Revitalization extract 1000 mg
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 ㎖Purified water was added to a total of 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
After mixing the above components in accordance with a conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions. Although the composition ratio is a composition that is relatively suitable for preference beverages as a preferred example, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, use purpose.
이와 같이 본 발명은 돼지감자 및 꾸지뽕잎의 복합추출물을 함유하는 각종 식품류 및 음료류를 제조함으로서 혈당강하 효과가 기대되는 기능성 식품을 제공할 수 있다.As such, the present invention can provide a functional food that is expected to have a hypoglycemic effect by preparing various foods and beverages containing a complex extract of pork potato and cuddle mulberry leaf.
Claims (7)
Porcine potato ( Helianthus tuberous ) and Cudrania tricuspidata ( Cudrania tricuspidata ) is a hypoglycemic complex extract mixed in a 3: 7 to 7: 3 weight ratio.
The complex extract according to claim 2, wherein the pork potato and cuddle leaves are mixed in a weight ratio of 4: 6 to 6: 4.
The complex extract according to claim 2, wherein the Pork Potato and Cudrania leaf extract are extracted by any one method selected from the group consisting of hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction and steam extraction.
The complex extract according to claim 4, wherein the Pork Potato and Cudrania leaf extract are extracted by hot water extraction.
Health functional food for improving blood sugar of diabetic patients containing the complex extract according to claim 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120058747A KR101359806B1 (en) | 2012-05-31 | 2012-05-31 | Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120058747A KR101359806B1 (en) | 2012-05-31 | 2012-05-31 | Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130134882A KR20130134882A (en) | 2013-12-10 |
KR101359806B1 true KR101359806B1 (en) | 2014-02-13 |
Family
ID=49982436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120058747A KR101359806B1 (en) | 2012-05-31 | 2012-05-31 | Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101359806B1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101662281B1 (en) * | 2015-11-04 | 2016-10-05 | 김태현 | process of jerusalem artichoke-wild ginseng drink and jerusalem artichoke-wild ginseng drink there by the same that |
KR102036962B1 (en) * | 2017-02-15 | 2019-10-25 | 동신대학교산학협력단 | Composition for Anti-Diabetes Using an Extract of Ecklonia cava etc. |
KR101952643B1 (en) * | 2017-10-26 | 2019-02-27 | 주식회사 보리로푸드시스템 | Preparation method of grain noodle |
KR102414431B1 (en) * | 2019-10-25 | 2022-07-01 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of diabetes mellitus |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060041438A (en) * | 2004-11-09 | 2006-05-12 | 이호운 | Functional food for regulating blood sugar including yerusalem artichoke |
KR100815212B1 (en) * | 2006-10-09 | 2008-03-19 | 조운행 | Antidiabetic and antiobese mixture of leaf extract of cudrania tricuspidata and digestion-resistant maltodextrin |
-
2012
- 2012-05-31 KR KR1020120058747A patent/KR101359806B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060041438A (en) * | 2004-11-09 | 2006-05-12 | 이호운 | Functional food for regulating blood sugar including yerusalem artichoke |
KR100815212B1 (en) * | 2006-10-09 | 2008-03-19 | 조운행 | Antidiabetic and antiobese mixture of leaf extract of cudrania tricuspidata and digestion-resistant maltodextrin |
Also Published As
Publication number | Publication date |
---|---|
KR20130134882A (en) | 2013-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102458434B (en) | Composition for increasing the bioavailability of saponin | |
KR101359806B1 (en) | Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same | |
KR101559130B1 (en) | Composition comprising herbal extract for preventing or treating obesity | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR20140034620A (en) | Composition for preventing or treating diabetbes mellitus disease containing extract of plants | |
KR101902932B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum | |
CN104800608A (en) | Traditional Chinese herbal medicine composition with hypotensive effect and application thereof | |
CN107569608A (en) | It is a kind of to be used for hypoglycemic pharmaceutical composition | |
KR101460126B1 (en) | Composition for preventing and improving sex hormone-related disease and symptoms comprising dandelion extract or dandelion containing multiple extract as an active ingredient | |
KR101895972B1 (en) | A composition for preventing or treating menopausal disorder comprising Tetragonia tetragonoides (Pall.) Kuntze extract | |
KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
KR102292059B1 (en) | Composition comprising of the extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating diabetic complication and diabetes | |
KR20140032961A (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
KR100543405B1 (en) | Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus | |
KR102045847B1 (en) | Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin | |
KR101350222B1 (en) | An alcohol detoxification composition comprising fruit extract of Camellia japonica | |
KR100927435B1 (en) | Pill type a healthy food for improving and alleviating the diabetes and preparation method thereof | |
KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
KR20200132261A (en) | Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR20200076185A (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle and onion | |
KR101641415B1 (en) | Composition comprising the combined extracts of Phlomis umbrosa, Astragalus membranceus, Discorea japonica, Acanthpanax senticosus and Angelica gigas for stimulating bone growth | |
KR101077546B1 (en) | A composition having antidiabetes activity consisting of Ligustrum fruit and red-ginseng Cheongkukjang powder | |
KR102233672B1 (en) | A composition for improving, preventing and treating of diabetes mellitus comprising Milk thistle and Helianthus tuberosus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180104 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20200107 Year of fee payment: 7 |